QUOTE AND NEWS
GenEng News  Dec 19  Comment 
Eli Lilly entered a licensing collaboration with French biotech Adocia to develop ultra-rapid insulin, known as BioChaperone Lispro, for the treatment of patients with type 1 and type 2 diabetes. Adocia will get $50 million upfront with the...
FierceBiotech  Dec 19  Comment 
Welcome to the latest edition of our weekly EuroBiotech Report.
Jutia Group  Dec 17  Comment 
[PR Newswire] - INDIANAPOLIS, Dec. 17, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2015 on Wednesday, January 7, 2015 and, separately, will announce its financial results ... Read more on this. ...
Forbes  Dec 16  Comment 
CVS Health (CVS) approved a 27% increase in its quarterly cash dividend, to $0.35 per share on the common stock of the company. This increase translates to $1.40 per share annually, up 30 cents per share. The quarterly dividend is payable on...
MarketWatch  Dec 15  Comment 
Eli Lilly said on Monday that it was increasing its quarterly dividend by 2% to 50 cents a share. The new dividend will be payable March 10, 2015 to shareholders of record as of Feb. 13. "The increase in our dividend signals continued confidence...
Wall Street Journal  Dec 12  Comment 
The U.S. Food and Drug Administration has approved Eli Lilly Co.’s Cyramza to treat non-small cell lung cancer, the most common type of lung cancer.
Financial Times  Dec 11  Comment 
Hopes that several of drugmaker’s products could be blockbusters
TheStreet.com  Dec 11  Comment 
NEW YORK (TheStreet) -- Shares of Eli Lilly and Co.  are up 2.04% to $72.50 in pre-market trading Thursday morning after Morgan Stanley upgraded company to "overweight" from "underweight" and raised its price target to $85 from $60. "Recent...
MarketWatch  Dec 11  Comment 
Morgan Stanley analyst David Risinger made a bullish U-turn on Eli Lilly's stock on Thursday, upgrading it to overweight after being at underweight for three years, because of increased optimism about the pharmaceutical giant's drug pipeline....
Wall Street Journal  Dec 9  Comment 
Eli Lilly and Incyte said that a late-stage study of a potential rheumatoid arthritis treatment met its primary endpoint.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki